Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% [6][9]. Core Insights - The company achieved a revenue of RMB 284.42 billion in 2024, representing a year-over-year growth of 10.07%. The net profit attributable to shareholders was RMB 10.17 billion, with a year-over-year increase of 23.51% [7]. - The express and large parcel segment accounted for 70.4% of the company's revenue, with a notable increase in volume and profit margins [2][10]. - The supply chain and international business segment showed signs of recovery, with a revenue increase of 17.72% year-over-year [7][10]. - The company plans to distribute a total dividend of approximately RMB 41.04 billion for 2024, reflecting a dividend payout ratio of about 40% [7]. Financial Performance - The company reported a net profit of RMB 10.17 billion for 2024, with projections for future profits of RMB 11.83 billion in 2025, RMB 13.60 billion in 2026, and RMB 15.20 billion in 2027, indicating a steady growth trajectory [9][11]. - The earnings per share (EPS) for 2024 is projected at RMB 2.11, with expected growth in subsequent years [9][11]. - The company's price-to-earnings (P/E) ratio is forecasted to decrease from 16.42 in 2024 to 11.36 by 2027, suggesting an attractive valuation over time [9][11]. Business Segments - The express and large parcel segment generated revenue of RMB 200.16 billion in 2024, with a net profit of RMB 10.98 billion, reflecting a profit margin of 5.49% [7][10]. - The same-city delivery segment saw a revenue increase of 22.24%, with net profit growth exceeding 160%, driven by increased order volumes and improved operational efficiency [10]. - The supply chain and international business segment recorded a revenue of RMB 74 billion, although it faced a net loss of RMB 1.32 billion due to restructuring efforts [7][10]. Market Position - The company maintains a strong competitive edge in the logistics sector, with a fleet of 110 aircraft and a significant ground transportation network, positioning it well to capitalize on the growing demand for logistics services [10]. - The report highlights the company's strategic focus on international expansion, with over 9,100 international cargo flights in 2024, marking a 19% increase year-over-year [7][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][12] Core Views - The company reported a revenue of 168.1 billion yuan in 2024, a year-on-year decrease of 6.2%, with a gross profit of 10.672 billion yuan, down 22.5% year-on-year, and a net profit attributable to shareholders of 3.212 billion yuan, down 36.0% year-on-year [6] - The company has a strong market position with 4.19 million active customers, a 10.7% year-on-year increase, and holds 14.1% of luxury car brand users in 32 major cities [6] - The company is expected to improve its market share despite industry challenges, with a focus on embracing new energy vehicles [6] Financial Performance Summary - In 2024, the company sold 485,300 new cars, a year-on-year decrease of 3.2%, with a gross loss of 3.208 billion yuan from new car sales [7] - The after-sales service revenue reached 22.001 billion yuan, a year-on-year increase of 9.6%, with a gross profit of 10.216 billion yuan, reflecting stable growth in after-sales business [8] - The company forecasts net profits of 3.519 billion yuan and 4.944 billion yuan for 2025 and 2026 respectively, with an estimated EPS of 1.5, 2.1, and 2.7 yuan for 2025, 2026, and 2027 [6][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company demonstrated resilience as a market leader, with stable overseas expansion [1] - In 2024, the company achieved total revenue of 95.06 billion yuan, a year-on-year increase of 10.82%, and a net profit attributable to shareholders of 5.86 billion yuan, up 10.16% year-on-year [7] - The company’s sales volume increased against industry trends, with domestic sales rising by 12.8% to 109,000 units, while the overall heavy truck industry saw a decline of 1.7% [7] - The gross margin slightly decreased to 15.6%, attributed to intense domestic price competition and changes in export market structure [7] - Effective cost control led to a slight increase in net profit margin to 7.0% [7] - The company’s earnings per share (EPS) for 2024 is projected at 2.12 yuan, with a price-to-earnings (P/E) ratio of 10.56 [1] Financial Summary - Total revenue forecast for 2024 is 95.06 billion yuan, with projections of 106.86 billion yuan for 2025 and 118.77 billion yuan for 2026 [1][8] - Net profit attributable to shareholders is expected to reach 6.84 billion yuan in 2025 and 8.16 billion yuan in 2026 [1][8] - The company’s cash and cash equivalents are projected to increase significantly from 19.08 billion yuan in 2024 to 110.79 billion yuan by 2027 [8] - The company maintains a strong balance sheet with a debt-to-asset ratio of 62.13% [6]

Investment Rating - The report maintains a "BUY" rating for Innovent Biologics, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - Innovent Biologics is entering a phase of sustainable profitability, having achieved a full-year non-IFRS net profit of RMB332 million in FY24, driven by strong product revenue growth and one-off license fee income [8]. - The target price has been revised upwards from HK$57.67 to HK$61.71, reflecting a 33.6% upside potential from the current price of HK$46.20 [3][8]. - The company is advancing its next-generation immuno-oncology (IO) therapies and antibody-drug conjugates (ADCs), with significant clinical programs underway [8]. Financial Summary - Revenue is projected to grow from RMB6,206 million in FY23 to RMB11,356 million in FY25, representing a year-on-year growth of 51.8% [2][13]. - Net profit is expected to turn positive in FY25, reaching RMB445.7 million, with EPS projected at RMB0.27 [2][11]. - R&D expenses are forecasted to remain stable, while gross profit margin is expected to expand to 84.9% in FY24 from 82.8% in FY23 [2][8]. Share Performance - The market capitalization of Innovent Biologics is approximately HK$75.68 billion, with a 52-week high of HK$51.15 and a low of HK$30.00 [3][4]. - The stock has shown strong performance, with a 1-month absolute return of 14.2% and a 3-month return of 29.8% [5]. Pipeline and Growth Potential - Innovent has a robust pipeline with over 10 ADC clinical programs and is focusing on combination trials with its next-generation IO therapy, IBI363 [8]. - The company aims to initiate multiple Phase 3 trials by 2030, targeting global markets with its innovative therapies [8].

31 Mar 2025 CMB International Global Markets | Equity Research | Company Update Li Ning (2331 HK) Conservative guidance but quite expected FY24 results were inline with market expectation while 4Q24 operating numbers were slightly better than expected. Going forward, on one hand, the Company is outlining conservative FY25E guidance and the plan to invest more for the future, and on the other hand, the numbers in 1Q25E are already trending better. Therefore, we tend to think the worst should have already gon ...

Investment Rating - The report maintains a "BUY" rating for Xunfei Healthcare, indicating a potential return of over 15% over the next 12 months [13]. Core Insights - Xunfei Healthcare reported a strong revenue growth of 32.0% YoY in 2024, reaching RMB 734.0 million, with a notable acceleration in growth from 17.8% in 1H24 to 39.6% in 2H24, driven by robust demand for medical AI services [1][2]. - The company improved its cost structure significantly, with SG&A expense ratio declining by 10.3 percentage points and R&D expense ratio falling by 10.4 percentage points, leading to a substantial narrowing of the net loss margin [1]. - Adjusted net loss narrowed by 21.4% YoY to RMB 44.8 million, with total R&D spending at RMB 296.8 million, representing 40.4% of revenue [1]. - The revenue mix improved, with hospital service revenue increasing by 103% YoY and patient service revenue rising by 57% YoY, indicating a shift towards higher contributions from both To B and To C segments [6]. - The company is well-positioned to lead the healthcare AI market, serving over 500 secondary and tertiary hospitals, including 40 of China's Top 100 hospitals [6]. Financial Summary - Revenue is projected to grow from RMB 734 million in 2024 to RMB 1,855 million by 2027, reflecting a CAGR of 37.9% from 2024 to 2026 [2][10]. - The adjusted net profit is expected to improve significantly, reaching RMB 120 million by 2027, with a YoY growth of 456.7% [2][10]. - The company’s net loss margin is projected to narrow from -8.10% in 2025E to 3.80% in 2027E, indicating a path towards profitability [7][11]. Market Position and Growth Potential - Xunfei Healthcare's data flywheel effect enhances its technological leadership, serving over 70,000 primary healthcare institutions and generating millions of AI-assisted diagnosis suggestions daily [6]. - The company maintains a leading position in the To G healthcare AI market, with a significant recovery in revenue from primary healthcare services in 2H24, increasing by 40% YoY [6]. - The target price for Xunfei Healthcare is set at HK$166.69, reflecting a 33.3% upside from the current price of HK$125.00 [3].

Investment Rating - The report maintains a BUY rating for CR MixC Lifestyle with a target price of HK$45.3, reflecting a 29% upside from the current price of HK$35.10 [3][8]. Core Insights - CR MixC's FY24 revenue increased by 15% YoY to RMB 17 billion, slightly missing guidance by 3%, primarily due to a decline in value-added services (VAS) [8]. - Net profit rose 24% YoY to RMB 3.6 billion, exceeding guidance by 4%, driven by strong performance in shopping mall operations and effective cost control [8][9]. - The company aims for double-digit net profit growth in FY25, with an estimated 21%+ core net profit growth required to meet the 14th Five-Year Plan targets [8][10]. Financial Performance - FY24 revenue: RMB 17,043 million, with a YoY growth of 15.4% [2]. - FY24 net profit: RMB 3,629 million, with a YoY growth of 23.9% [2]. - The gross profit margin improved to 32.9% in FY24, up from 31.8% in FY23 [9][14]. - The company declared a 100% dividend payout based on core net profit, increasing the basic payout ratio to 60% from 55% in FY23 [8][10]. Revenue Breakdown - Shopping mall revenue surged by 30% YoY, contributing significantly to overall revenue growth [8]. - Urban space revenue increased by 36% YoY, supported by a 20% rise in managed gross floor area (GFA) and improved collection rates [8][9]. - Non-owner VAS revenue declined by 12% YoY, while owner VAS saw a 6% increase [8]. Future Projections - FY25E revenue is projected to reach RMB 19,821 million, reflecting a 16.3% YoY growth [2]. - FY25E net profit is estimated at RMB 4,321 million, indicating a 19.1% YoY growth [2]. - The company expects to maintain a strong growth trajectory, with a focus on expanding its shopping mall operations and enhancing third-party services [8][10].

Investment Rating - The report maintains a "BUY" rating for Carote Ltd, with a target price of HK$6.44, reflecting a potential upside of 16% from the current price of HK$5.55 [3][10]. Core Insights - Carote Ltd's FY24 net profit was in line with expectations, but sales faced pressure, leading to a cautious outlook for FY25E with a forecasted 7% net profit drop [1][10]. - Despite macroeconomic headwinds, management remains optimistic about achieving a sales growth target of over 30% for FY25E, particularly in the US and Western Europe markets [9][10]. - The company is expected to experience a decline in gross profit margins due to import tariffs and other macro uncertainties, with projections of 35.2% and 33.6% for FY25E and FY26E, respectively [10][11]. Financial Summary - Revenue for FY24 was reported at RMB 2,073 million, representing a 31% year-over-year growth, while net profit surged by 50% to RMB 356 million [2][10]. - For FY25E, revenue is forecasted to be RMB 2,560 million, with a year-over-year growth rate of 23.5% [2][11]. - The company's gross profit margin for FY24 was 40.3%, exceeding estimates, but is expected to decline in the following years [10][11]. Market Performance - Carote Ltd's market capitalization is approximately HK$3,080.3 million, with an average turnover of HK$6.3 million over the past three months [4]. - The share performance over the last month showed an increase of 4.7%, while the three-month performance was up by 11% [6]. Shareholding Structure - The major shareholders include Yili Investment & Carote CM, holding 72.4%, and cornerstone investors holding 9.8% [5].

31 Mar 2025 Earnings Summary | (YE 31 Dec) | FY23A | FY24A | FY25E | FY26E | FY27E | | --- | --- | --- | --- | --- | --- | | Revenue (RMB mn) | 85,041 | 95,062 | 99,522 | 106,172 | 110,655 | | YoY growth (%) | 43.4 | 11.8 | 4.7 | 6.7 | 4.2 | | Net profit (RMB mn) | 5,318.1 | 5,858.4 | 6,025.2 | 6,314.8 | 6,567.9 | | EPS (Reported) (RMB) | 1.93 | 2.14 | 2.18 | 2.29 | 2.38 | | YoY growth (%) | 196.0 | 10.9 | 2.1 | 4.8 | 4.0 | | Consensus EPS (RMB) | na | 2.23 | 2.52 | 2.84 | 0.00 | | P/E (x) | 10.9 | 9.8 | 9. ...

Investment Rating - The investment rating for BYD Electronics is "Buy" (maintained) [1] Core Views - The company reported a robust performance in 2024, with total revenue reaching 177.3 billion yuan, a year-on-year increase of 36.0%, and a net profit attributable to shareholders of 4.27 billion yuan, up 5.6% year-on-year [7] - The consumer electronics segment showed significant growth, with revenue increasing by 45.0% to 141.23 billion yuan, driven by strong performance in components and assembly businesses [7] - The automotive electronics sector is expected to benefit from the parent company's advancements in smart technology, with revenue projected to grow by 45.5% to 20.51 billion yuan in 2024 [7] - The company is enhancing its AI and robotics capabilities, with new intelligent products contributing to growth despite a slight decline in revenue from new products [7] Financial Summary - Total revenue forecast for 2024 is 177.3 billion yuan, with a projected growth rate of 35.97% for 2025 [1][8] - Net profit attributable to shareholders is expected to reach 5.26 billion yuan in 2025, reflecting a growth rate of 23.42% [1][8] - The earnings per share (EPS) is projected to be 1.89 yuan for 2024, increasing to 2.34 yuan in 2025 [1][8] - The price-to-earnings (P/E) ratio is forecasted to be 16.18 for 2025, indicating a favorable valuation [1][8]